PROTHENA CORP PUBLIC LTD CO (PRTA)
PROTHENA CORP PUBLIC LTD CO (PRTA) from its SEC filings: 2025 revenue $9.7 million (-93% vs the year before), net margin -2521%, free cash flow -$163.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $9.7 million |
| Revenue growth | -93% |
| Net income | -$244.1 million |
| Net margin | -2520.6% |
| Free cash flow | -$163.6 million |
| Diluted EPS | $-4.53 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -77% |
| Cash | $288.2 million |
| Share count, 1 year | -5% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-22. Education only, not financial advice.